cGAS activation in classical dendritic cells causes autoimmunity in TREX1-deficient mice
Detection of cytosolic DNA by the cyclic GMP-AMP (cGAMP) synthase (cGAS)-stimulator of interferon genes (STING) pathway provides immune defense against pathogens and cancer but can also cause autoimmunity when overactivated. The exonuclease three prime repair exonuclease 1 (TREX1) degrades DNA in the cytosol and prevents cGAS activation by self-DNA. Loss-of-function mutations of the TREX1 gene are linked to autoimmune diseases such as Aicardi-Goutières syndrome, and mice deficient in TREX1 develop lethal inflammation in a cGAS-dependent manner. In order to determine the type of cells in which cGAS activation drives autoinflammation, we generated conditional cGAS knockout mice on the Trex1<sup>-/-</sup> background. Here, we show that genetic ablation of the cGAS gene in classical dendritic cells (cDCs), but not in macrophages, was sufficient to rescue Trex1<sup>-/-</sup> mice from all observed disease phenotypes including lethality, T cell activation, tissue inflammation, and production of antinuclear antibodies and interferon-stimulated genes. These results show that cGAS activation in cDC causes autoinflammation in response to self-DNA accumulated in the absence of TREX1.
Authors
- Zhijian J. Chen (ORCID: https://orcid.org/0000-0002-8475-8251)
- Junjiao Wu
- Yafang Deng (ORCID: https://orcid.org/0000-0001-5524-9629)
- Seoyun Yum (ORCID: https://orcid.org/0000-0003-0226-4774)
- Minghao Li (ORCID: https://orcid.org/0000-0002-1456-2691)
- Xiaoxia Zuo
- Tong Li (ORCID: https://orcid.org/0000-0003-3725-1420)
- Lijun Sun
Institutions
- Central South University (CN)
- Xiangya Hospital Central South University (CN)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1073/pnas.2411747121
- Citations
- 8
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 1.92
Funders
- Howard Hughes Medical Institute
- Cancer Research UK
- National Cancer Institute